Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer | SpringerLink
Precision oncology in metastatic colorectal cancer — from biology to medicine | Nature Reviews Clinical Oncology
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression | PLOS ONE
Frontiers | Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review
HER2 expression and copy number alterations in colorectal cancer (CRC).... | Download Scientific Diagram
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - Annals of Oncology
![PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/902d0b938fec74e846b6e114a899720dcadb2ead/33-Figure1-1.png "PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar")
PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar
Gastrointestinal cancers: new standards of care from landmark trials | MDedge Hematology and Oncology
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial - ESMO Open
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial - ESMO Open
Q&A column - CAP TODAY
Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues | JCO Oncology Practice
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer
Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
PDF) Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial | Nature Medicine
![PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/902d0b938fec74e846b6e114a899720dcadb2ead/34-Figure2-1.png "PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar")
PDF] Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. | Semantic Scholar
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target | American Society of Clinical Oncology Educational Book
Update systemic therapy in solid tumor
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm - Cancer Treatment Reviews
Q&A column - CAP TODAY
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
Gastrointestinal cancers: new standards of care from landmark trials | MDedge Hematology and Oncology
![HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/8602/1/fig-1-full.png "HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]")
HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China [PeerJ]
